CY1107509T1 - Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων - Google Patents
Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεωνInfo
- Publication number
- CY1107509T1 CY1107509T1 CY20071101633T CY071101633T CY1107509T1 CY 1107509 T1 CY1107509 T1 CY 1107509T1 CY 20071101633 T CY20071101633 T CY 20071101633T CY 071101633 T CY071101633 T CY 071101633T CY 1107509 T1 CY1107509 T1 CY 1107509T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aminotheasols
- cycline
- addictive
- suspensions
- movements
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Ενώσεις του τύπου (I) και φαρμακευτικώς παραδεκτά άλατα αυτών. Όπως χρησιμοποιούνται στον τύπο (I) και σε ολόκληρη την περιγραφή, τα σύμβολα έχουν τις ακόλουθες σημασίες: R1 και R2 είναι ανεξάρτητα υδρογόνο, φθόριο ή αλκύλιο· R3 είναι αρύλιο ή ετεροαρύλιο. Οι ενώσεις του τύπου (I) είναι αναστολείς πρωτεϊνικής κινάσης και είναι χρήσιμες στην θεραπευτική αγωγή και πρόληψη πολλαπλασιαστικών ασθενειών, για παράδειγμα καρκίνου, φλεγμονής και αρθρίτιδας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6519597P | 1997-11-12 | 1997-11-12 | |
EP98956431A EP1042307B1 (en) | 1997-11-12 | 1998-11-02 | Aminothiazole inhibitors of cyclin dependent kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107509T1 true CY1107509T1 (el) | 2013-03-13 |
Family
ID=22060972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101633T CY1107509T1 (el) | 1997-11-12 | 2007-12-27 | Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων |
Country Status (32)
Country | Link |
---|---|
US (1) | US6040321A (el) |
EP (1) | EP1042307B1 (el) |
JP (1) | JP4344084B2 (el) |
KR (2) | KR100454426B1 (el) |
CN (1) | CN1160343C (el) |
AR (1) | AR017182A1 (el) |
AT (1) | ATE374771T1 (el) |
AU (1) | AU730607B2 (el) |
BR (1) | BR9814124A (el) |
CA (1) | CA2309551C (el) |
CO (1) | CO4990957A1 (el) |
CY (1) | CY1107509T1 (el) |
CZ (1) | CZ297907B6 (el) |
DE (1) | DE69838515T2 (el) |
DK (1) | DK1042307T3 (el) |
EG (1) | EG24028A (el) |
ES (1) | ES2296347T3 (el) |
HU (1) | HUP0004559A3 (el) |
ID (1) | ID23983A (el) |
IL (1) | IL135589A (el) |
MY (1) | MY120779A (el) |
NO (1) | NO316773B1 (el) |
NZ (1) | NZ503828A (el) |
PE (1) | PE131699A1 (el) |
PL (1) | PL204642B1 (el) |
PT (1) | PT1042307E (el) |
RU (1) | RU2211839C2 (el) |
TR (1) | TR200001344T2 (el) |
TW (1) | TW593292B (el) |
UY (1) | UY25239A1 (el) |
WO (1) | WO1999024416A1 (el) |
ZA (1) | ZA9810332B (el) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
US6214852B1 (en) * | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6337338B1 (en) * | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
TR200101871T2 (tr) * | 1998-12-22 | 2001-10-22 | Warner-Lambert Company | Kombine kemoterapi |
US20040171632A1 (en) * | 1998-12-22 | 2004-09-02 | Gowan Richard Carleton | Combination chemotherapy |
CN1148349C (zh) * | 1999-04-07 | 2004-05-05 | 参天制药株式会社 | N-取代-N′-取代脲衍生物及其用作TNF-α生成抑制剂的用途 |
EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
ES2251395T3 (es) | 1999-07-26 | 2006-05-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de biarilureas. |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
US6392053B2 (en) * | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
MY125768A (en) * | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
EP1274706A1 (en) | 2000-04-18 | 2003-01-15 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
US6534531B2 (en) | 2000-04-27 | 2003-03-18 | Bristol-Myers Squibb Company | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy |
AU2001264376A1 (en) * | 2000-06-15 | 2001-12-24 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
EP1303513A1 (en) * | 2000-07-26 | 2003-04-23 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
MXPA03001189A (es) * | 2000-08-09 | 2004-05-14 | Agouron Pharma | Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas. |
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
ES2257461T3 (es) * | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
EP1353668B1 (en) | 2001-01-25 | 2008-03-19 | Bristol-Myers Squibb Company | Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer |
CZ302848B6 (cs) * | 2001-03-19 | 2011-12-14 | Novartis Ag | Kombinace protiprujmového cinidla a derivátu epothilonu |
EP1256578B1 (en) | 2001-05-11 | 2006-01-11 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
AU2002342878A1 (en) * | 2001-05-16 | 2002-11-25 | Axxima Pharmaceuticals Ag | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
EP1397137B1 (en) | 2001-05-25 | 2009-10-14 | Bristol-Myers Squibb Company | Hydantion derivatives as inhibitors of matrix metalloproteinases |
HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
WO2003008365A2 (en) * | 2001-07-19 | 2003-01-30 | Pharmacia Italia S.P.A. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
HUP0402341A3 (en) * | 2001-08-31 | 2005-11-28 | Bristol Myers Squibb Company P | Compositions containing thiazol-2-ylamines for the treatment of cancer |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
ATE362474T1 (de) * | 2002-09-04 | 2007-06-15 | Schering Corp | Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
ES2285164T3 (es) * | 2002-09-04 | 2007-11-16 | Schering Corporation | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. |
CN1701074A (zh) * | 2002-09-04 | 2005-11-23 | 先灵公司 | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 |
US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
NZ539163A (en) * | 2002-09-04 | 2007-03-30 | Schering Corp | Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors |
EP1549626A1 (en) * | 2002-10-03 | 2005-07-06 | Novartis AG | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
JP4390704B2 (ja) | 2002-10-03 | 2009-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | グルコキナーゼ(gk)活性化物質としてのインドール−3−カルボキシアミド |
KR20050071598A (ko) * | 2002-10-24 | 2005-07-07 | 메르크 파텐트 게엠베하 | 라프-키나아제 억제제로서의 메틸렌 우레아 유도체 |
AU2003302084A1 (en) * | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
US20070105114A1 (en) * | 2003-07-29 | 2007-05-10 | Martha Li | Biomarkers of cyclin-dependent kinase modulation |
US6949895B2 (en) * | 2003-09-03 | 2005-09-27 | Axcelis Technologies, Inc. | Unipolar electrostatic quadrupole lens and switching methods for charged beam transport |
US7256208B2 (en) * | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス, インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
WO2005072731A1 (en) * | 2004-01-29 | 2005-08-11 | X-Ceptor Therapeutics, Inc. | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
AU2005210474B2 (en) * | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7696241B2 (en) * | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
AR052142A1 (es) | 2004-11-18 | 2007-03-07 | Bristol Myers Squibb Co | Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma |
US20100105745A1 (en) * | 2005-01-04 | 2010-04-29 | Toshinari Minamoto | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta |
JPWO2006073202A1 (ja) * | 2005-01-04 | 2008-08-07 | 国立大学法人金沢大学 | GSK3β阻害効果に基づくがんの抑制および抗がん剤の評価方法 |
ATE547396T1 (de) | 2005-07-08 | 2012-03-15 | Novo Nordisk As | Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren |
AU2006268589B2 (en) * | 2005-07-14 | 2011-09-29 | Vtv Therapeutics Llc | Urea glucokinase activators |
CN101365700A (zh) * | 2005-11-15 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氮杂吲唑 |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7888504B2 (en) * | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
US20080188524A1 (en) * | 2006-10-25 | 2008-08-07 | Martin Augustin | Methods of treating pain |
WO2008070672A2 (en) | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
MX2012013031A (es) | 2010-05-12 | 2012-12-17 | Univ Vanderbilt | Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica. |
US9376664B2 (en) | 2010-06-14 | 2016-06-28 | The Scripps Research Institute | Reprogramming of cells to a new fate |
AU2011323682B2 (en) * | 2010-11-01 | 2016-06-23 | Romark Laboratories L.C. | Alkylsulfinyl-substituted thiazolide compounds |
AU2012207142B2 (en) | 2011-01-20 | 2017-04-27 | Board Of Regents, The University Of Texas System | MRI markers, delivery and extraction systems, and methods of manufacture and use thereof |
CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2924044B1 (en) | 2012-11-17 | 2018-10-31 | Beijing Shuobai Pharmaceutical Co., LTD | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
AU2014236719B2 (en) | 2013-03-15 | 2018-06-21 | The California Institute For Biomedical Research | Compounds and methods for inducing chondrogenesis |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
TWI706940B (zh) * | 2016-04-06 | 2020-10-11 | 德商創新分子有限責任公司 | 新穎之抗病毒化合物 |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
WO2019068817A1 (en) | 2017-10-05 | 2019-04-11 | Innovative Molecules Gmbh | SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS |
CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
CA3194868A1 (en) * | 2020-10-16 | 2022-04-21 | Georg Winter | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1088049A (en) * | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
NO831160L (no) * | 1982-04-08 | 1983-10-10 | Erba Farmitalia | Fremstilling av substituerte penem-derivater |
JPS6339868A (ja) * | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
DE4119756A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung |
JPH0859669A (ja) * | 1994-06-13 | 1996-03-05 | Takeda Chem Ind Ltd | セフェム化合物、その製造法及び剤 |
-
1998
- 1998-10-21 US US09/176,239 patent/US6040321A/en not_active Expired - Lifetime
- 1998-11-02 AU AU12955/99A patent/AU730607B2/en not_active Ceased
- 1998-11-02 BR BR9814124-4A patent/BR9814124A/pt not_active Application Discontinuation
- 1998-11-02 DK DK98956431T patent/DK1042307T3/da active
- 1998-11-02 IL IL13558998A patent/IL135589A/en not_active IP Right Cessation
- 1998-11-02 EP EP98956431A patent/EP1042307B1/en not_active Expired - Lifetime
- 1998-11-02 JP JP2000520430A patent/JP4344084B2/ja not_active Expired - Fee Related
- 1998-11-02 PL PL340540A patent/PL204642B1/pl not_active IP Right Cessation
- 1998-11-02 NZ NZ503828A patent/NZ503828A/xx active Application Revival
- 1998-11-02 RU RU2000115305/04A patent/RU2211839C2/ru not_active IP Right Cessation
- 1998-11-02 DE DE69838515T patent/DE69838515T2/de not_active Expired - Lifetime
- 1998-11-02 KR KR10-2000-7004995A patent/KR100454426B1/ko not_active IP Right Cessation
- 1998-11-02 CN CNB988110911A patent/CN1160343C/zh not_active Expired - Fee Related
- 1998-11-02 WO PCT/US1998/023197 patent/WO1999024416A1/en active IP Right Grant
- 1998-11-02 CA CA002309551A patent/CA2309551C/en not_active Expired - Fee Related
- 1998-11-02 CZ CZ20001744A patent/CZ297907B6/cs not_active IP Right Cessation
- 1998-11-02 ES ES98956431T patent/ES2296347T3/es not_active Expired - Lifetime
- 1998-11-02 TR TR2000/01344T patent/TR200001344T2/xx unknown
- 1998-11-02 ID IDW20000894A patent/ID23983A/id unknown
- 1998-11-02 AT AT98956431T patent/ATE374771T1/de active
- 1998-11-02 KR KR10-2003-7004561A patent/KR20030036862A/ko not_active Application Discontinuation
- 1998-11-02 PT PT98956431T patent/PT1042307E/pt unknown
- 1998-11-02 HU HU0004559A patent/HUP0004559A3/hu unknown
- 1998-11-09 TW TW087118625A patent/TW593292B/zh not_active IP Right Cessation
- 1998-11-09 UY UY25239A patent/UY25239A1/es not_active IP Right Cessation
- 1998-11-11 ZA ZA9810332A patent/ZA9810332B/xx unknown
- 1998-11-11 CO CO98066514A patent/CO4990957A1/es unknown
- 1998-11-12 EG EG140698A patent/EG24028A/xx active
- 1998-11-12 AR ARP980105716A patent/AR017182A1/es unknown
- 1998-11-12 PE PE1998001093A patent/PE131699A1/es not_active Application Discontinuation
- 1998-11-12 MY MYPI98005150A patent/MY120779A/en unknown
-
2000
- 2000-04-27 NO NO20002153A patent/NO316773B1/no not_active IP Right Cessation
-
2007
- 2007-12-27 CY CY20071101633T patent/CY1107509T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107509T1 (el) | Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων | |
CY1105618T1 (el) | Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης | |
CY1118498T1 (el) | Παραγωγα πυριδαζινονης | |
CY1114708T1 (el) | Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης | |
EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
BRPI0411365A (pt) | derivados de aminopiridina | |
CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
EE200200148A (et) | Kinasoliini derivaadid, nende valmistamise meetodning kasutamine | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
CY1105250T1 (el) | Μεθοδος θepαπευτικης αγωγης καταστασεων σχετιζομενων με κιναση ρ38 και ενωσεις πυρρολοτριαζινης χρησιμες ως αναστολεις της κινασης | |
CY1105075T1 (el) | Παραγωγα ινδολων και η χρησιμοποιηση τους σαν αναστολεις της φωσφοδιεστepασης 4 | |
EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
ATE302775T1 (de) | Carbolinderivate | |
BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
ATE346067T1 (de) | Carbolinderivate | |
CY1108061T1 (el) | Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης | |
CY1110284T1 (el) | Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο | |
DE69924292D1 (de) | Pyrazol verbindungen und ihre verwendung | |
BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
EA200400475A1 (ru) | Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли | |
NO20044526L (no) | Hemisterlinderivater og anvendelser derav | |
ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
ATE128128T1 (de) | Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one. | |
ES2104174T3 (es) | Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos. |